Immunotherapy in multiple myeloma

This article was originally published here

Cancer Treat Res Commun. 2021 Oct 2;29:100468. doi: 10.1016/j.ctarc.2021.100468. Online ahead of print.

ABSTRACT

Despite available therapies, Multiple Myeloma (MM) remains an incurable hematologic malignancy. Over the past three decades, there have been tremendous developments in therapeutic options for MM. In regards to immunotherapy, Daratumumab was the first monoclonal antibody to receive FDA approval for multiple myeloma. Since then, other monoclonal antibodies such as elotuzumab and isatuximab have received FDA approval. Many clinical trials are underway investigating the efficacy of newer immunotherapies. This review summarizes recently presented and/or published data regarding this growing field, specifically regarding monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and trispecific antibodies.

PMID:34653747 | DOI:10.1016/j.ctarc.2021.100468